Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Our findings underscore the dynamic nature of prostate tumor biology and emphasize the need for translational research to validate preclinical hypotheses in clinically relevant settings, ultimately improving trial design and therapeutic strategies.
Authors
- Gerhardt Attard (ORCID: https://orcid.org/0000-0002-4811-7983)
- Matthew J. Wongchenko (ORCID: https://orcid.org/0000-0003-1230-7117)
- Ethan Sokol (ORCID: https://orcid.org/0000-0002-5480-8473)
- Armande Ang Houle (ORCID: https://orcid.org/0000-0003-1161-5927)
- Shu Wang (ORCID: https://orcid.org/0000-0002-9328-3710)
- Matthew H. Secrest (ORCID: https://orcid.org/0000-0002-0939-4902)
- Ciara Metcalfe (ORCID: https://orcid.org/0000-0001-7233-661X)
- Dexter X. Jin (ORCID: https://orcid.org/0000-0001-6545-1580)
- Kalpit Shah (ORCID: https://orcid.org/0000-0001-6383-4625)
- Steven Gendreau (ORCID: https://orcid.org/0009-0009-4599-7151)
- Małgorzata Nowicka (ORCID: https://orcid.org/0000-0002-5918-5981)
- Yuxiang Zhang (ORCID: https://orcid.org/0000-0002-5110-5684)
- Carsten Schröder (ORCID: https://orcid.org/0000-0002-9785-9617)
- Dan Canter
- Wei Zhou
Institutions
- Roche (Switzerland) (CH)
- Boston Foundation (US)
- Genesys (United States) (US)
- GlobalFoundries (United States) (US)
- Gene Therapy Laboratory (FR)
- Genesis Research Institute (JP)
- Bioinformatics Institute (SG)
- Statistical Research (United States) (US)
- Foundation Medicine (United States)
- University College London (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1812
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Abbott Laboratories
- Pfizer
- AstraZeneca
- Sanofi
- Astellas Pharma
- Ipsen